Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682355 · ClinicalTrials.gov registry record
Optimizing Clinical Use of Polymyxin B
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 155
- Enrollment target
NCT02682355: Completed study, sponsored by Rutgers, The State University of New Jersey.
NCT02682355 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 155 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02682355 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
Study Summary
Polymyxin B is already being used extensively in the USA and other parts of the world; its use is likely to rapidly increase due to the greater burden of infections caused by MDR Gram-negative bacteria and the growing awareness of the limitations inherent in the clinical pharmacology of CMS/colistin. Cross resistance exists between the two polymyxins and thus both must be dosed optimally; but the recently generated scientifically-based dosage regimens for CMS/colistin cannot be extrapolated to polymyxin B. It is essential that an adequately powered study is conducted to define the clinical PK/PD/TD relationships of polymyxin B and identify, using next-generation proteomics, biomarkers for early detection of kidney injury. This will allow the development of scientifically-based dosage regimens for various categories of patients and an adaptive feedback control clinical tool for optimized dosing of polymyxin B in future individual patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2016-02 |
| Est. Completion | 2022-08-03 |
What the finished NCT02682355 record still lists
NCT02682355 is an observational study that tracks outcomes without assigning an intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02682355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02682355 about?
NCT02682355 is a clinical study titled "Optimizing Clinical Use of Polymyxin B". Polymyxin B is already being used extensively in the USA and other parts of the world; its use is likely to rapidly increase due to the greater burden of infections caused by MDR Gram-negative bacteria and the growing awareness of the limitations inherent in the clinical pharmacology of CMS/colistin...
What is the current status of trial NCT02682355?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2016-02. Estimated completion is 2022-08-03.
Who is sponsoring clinical trial NCT02682355?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia